Diabetes mellitus is a condition in which the pancreas no longer produces enough insulin or when cells stop responding to the insulin that is produced, so that glucose in the blood cannot be absorbed into the cells of the body. Symptoms include frequent urination, lethargy, excessive thirst, and hunger. The treatment includes changes in diet, oral medications, and in some cases, daily injections of insulin.
Is inhaled insulin delivery still a possibility? Why has it been a commercial failure? – The commercial failure of Exubera (Pfizer, New York, NY), the first inhaled insulin product to come to market, led other companies such as Eli Lilly-Alkermes to halt studies of similar drug delivery in development intended to compete for a share of the lucrative diabetes market.
Found: A gene that may play a role in type 1 diabetes – Stanford University’s researchers have identified a gene that may play a role in the development of type 1 diabetes, an autoimmune disease in which the immune system attacks the body’s insulin-producing cells.
Treatment with antipsychotic drugs is associated with a significantly increased risk of hospitalization for hyperglycemia in old patients. – Older patients with diabetes who take antipsychotic medications appear to have an increased risk of hospitalization for hyperglycemia (elevated blood glucose level), especially soon after beginning treatment, revealed by researchers.
Link between obesity and diabetes discovered, it may lead to the design of a drug to prevent the diabetes disease. – A critical link between obesity and the onset of Type 2 diabetes is established by a Monash University study in Australia. The new findings could lead to the design of a drug to prevent the disease.
Higher Levels of a Certain Protein Associated With Lower Risk of Type 2 Diabetes – Persons with higher levels of adiponectin, a protein that is produced by fat cells and that has anti-inflammatory and insulin-sensitizing properties, have an associated lower risk of type 2 diabetes.
Takeda receives FDA Complete Response letter for alogliptin, an investigational treatment for type 2 diabetes. – US top most health agency FDA has asked Takeda to conduct an additional clinical trial to rule out any adverse effects of alogliptin in relation to heart, that means Takeda needs to conduct a cardiovascular safety trial for alogliptin.
Glucose challenge test is accurate and economical for diabetes and prediabetes screening – Glucose challenge test commonly used to help identify women with diabetes during pregnancy may be an accurate, convenient and inexpensive way to screen the general population for unrecognized diabetes and prediabetes.
Novo Nordisk Warns Customers About Stolen Insulin — FDA Issues Public Health Advisory Regarding Levemir Insulin. – Novo Nordisk product previously reported as stolen in North Carolina has resurfaced recently at a medical center in Houston.
Diabetes patients should have regular exercise and weight training — Regular exercise can reduce or eliminate the need for medication in some patients with type 2 diabetes. – To reduce heart or cardiovascular risk, people with type 2 diabetes should do at least two-and-a-half hours per week of moderate-intensity or one-and-a-half hours per week of vigorous-intensity aerobic exercises, plus some weight training.
LSUHSC researchers first to document early signs for diabetes in kids as young as 7 – Research conducted under the direction of Melinda Sothern, PhD, Professor and Director of Health Promotion at the LSU Health Sciences Center New Orleans School of Public Health, showing early signs of diabetes in healthy children as young as seven years old will be presented at the American Diabetes Association 2009 Annual Scientific Session Meeting in New Orleans.
Large, long-term study shows Avandia has no increased overall cardiovascular risk compared to other commonly used diabetes medicines – Clinical trial results presented at the American Diabetes Association annual meeting show that overall rates of cardiovascular hospitalization and cardiovascular death are similar in patients taking Avandia (rosiglitazone) compared to those receiving metformin and sulfonylurea.
Ahmedabad based pharmaceutical company Zydus Cadila has filed IND (Investigational New Drug) application for anti diabetic and anti obesity drug with Drugs Controller General of India (DCGI). – Zydus Cadila, a global healthcare provider and one of India’s leading healthcare companies, has filed IND (Investigational New Drug) application for anti diabetic and anti obesity drug with Drugs Controller General of India (DCGI).
